Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-051733

Chief Business Development Off sold 417 shares at $45.51 ($18,978)

  • Chief Business Development Off acquired 417 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-09-21 Option exercise +417 $6.27 $2,615 417 D: show line 1 in the form
BENZENO SHARON Chief Business Development Off 2020-09-21 Sale −417 $45.51 $18,978 0 D: show line 2 in the form
Open-market sales · 417 sh · avg $45.51 · $18,978

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-09-21 Option exercise · Stock Option (Right to Buy) −417 2,917 D: show line 3 in the form
Loading xslF345X03/doc4.xml…